Investor Presentation on Unaudited Financial Results as of 30th June 2026

30th July 2026 The Manager-Listing The Manager- Listing BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Bandra (E) Mumbai-400001 Mumbai-400051 BSE Code-537291 NSE Code-NATHBIOGEN Dear Sir/Madam, Subject- Presentation on Unaudited financial results. Please find the attached herewith, presentation on Unaudited financial results for the period ended 30th June 2026. You are requested to take the above information on record. Thanking You. Yours faithfully, For Nath Bio-Genes (India) Limited, Amol Gupta Chief Financial Officer Nath Bio-Genes (I) Ltd. Investor Presentation Q1 & FY27 www.nathbiogenes.com Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward- looking statements. Nath Bio Genes (India) Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward- looking statements to reflect subsequent events or circumstances. Competitive Positioning In A Tough Sector Focus Area Winning Strategies Product Selection • Focus on Cotton, Wheat, Maize & • Build a dream-product basket with Fodder Bajra superior and diversified products • Empower Stakeholders; Build long- • Build an Un-paralleled Supply Chain term, loyal, symbiotic relationships with Network our production growers and organisers. Network of approximately 20,000 distributors and dealers, 17 branch offices, 10 processing plants, and warehouses spread across 23 states of India 3 What Our Business Delivered In Last 9 Years Average Selling Price (Rs/kg) is Increasing Revenue Growth (INR Mn) 1,244 CAGR 12.5% 4,316 1,917 FY18 FY26 FY19 FY26 Field Crops Vegetables Tailor Made Products Understand key farmer requirements based on deep market research. Develop products to suit various agri climatic conditions Focus on disease and pest resistance which automatically results in higher yield Stringent multistage trials before commercial development R&D Team of experienced scientists and experts Focused on R&D 2 Prioritize Disease and Pest resistance breeding 3 Large and Diverse collection of Germplasm Well Invested, DSIR recognized R&D Innovation Centres Produce Genetically Pure and Premium Quality Seeds Cold storage facilities, warehouses, and conditioning godowns having a capacity of 25,000MT Focused on Shareholder Value Creation Growing Business Product Excellence Differentiated Margin Expansion Customer Experience Strong Positions in Innovation and Expanding market Growing EBITDA important crops solution that drive reach through new margins through productivity and and innovative efficient operations create value for products such as farmers Sanket Farming Community’s Testimonials Q1 & FY27 PERFORMANCE Key Business Highlights Cotton, Bajra, and Jowar maintained stable volume and value Maize recorded 44% growth in volume and 59% growth in value Paddy registered 19% growth in volume and 34% growth in value, primarily driven by a higher contribution from premium-value products The PNS segment recorded 18% growth in volume and 25% growth in value All the above figures are on a quarter-on-quarter (QoQ) basis. Key Financial Highlights – FY26 Q1FY27 Q1FY26 YoY Revenue ▲ 15% ₹ 3,228 Mn ₹ 2,802 Mn Gross Profit ▲ 13% ₹ 1,629 Mn ₹ 1,438 Mn EBITDA ▲ 17% ₹ 351 Mn ₹ 299Mn PBT after Adjustment of ▲ 12% ₹ 334 Mn ₹ 299 Mn Exceptional Items Segmental Revenue Contribution Q1FY27 Revenue Q1FY26 Revenue INR 3,228 Mn INR 2,802Mn Others Others, Cotton 31% 30% 34% Cotton, Paddy Paddy, 35% 30% Cotton Paddy Others Cotton Paddy Others • Others include: Jowar, Bajra, Maize, Mustard, Wheat 2233 Income Statement Particulars (INR Mn) Q1FY27 Q1FY26 %Change(YoY) FY26 FY25 %Change(YoY) Total Revenue 3,228 2,802 15% 4,316 3,623 19% Gross Profit 1,629 1,438 13% 2,403 2,289 5% Gross Margin (%) 50% 51% 56% 63% EBITDA 351 299 17% 525 523 0% EBITDA Margin (%) 11% 11% 12% 14% Depreciation 10 10 3% 39 38 4% Finance Cost 38 29 31% 133 96 38% Other Income 19 18 8% 78 47 65% PBT (after adjustment of exceptional item) 334 299 12% 491 441 11% Tax 7 7 9% 47 20 135% Tax Rate (%) 2.2% 2.2% 11% 5% 137% PAT for the Period (excluding extra ordinary 327 292 12% 384 416 -8% items ) EPS 17.18 15.37 12% 23.42 22 6% Note - PAT is after adjusting for exceptional item APPENDIX 2255 Maintaining Profitability; Strong Balance Sheet Net Debt (INR Mn) Net Worth (INR Mn) 6,893 6,487 6,133 6,107 5,734 5,576 888 5,420 5,076 4,692 679 659 672 478 510 3,033 207 1,0711,213 -121 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 EBITDA Margin (%) PAT Margin (%) 18% 18% 22% 17% 19% 19% 15% 15% 16% 15% 12% 12% 14% 11% 13% 10% 12% 9% 9% FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 Visionary Leadership; Attracting the Best Talent Leadership Team Mr. Nandkishor Kagliwal Dr. Capt. Devinder Khurana Mr. Amol Gupta Chairman Executive Vice President CFO Dr. V. N. Kulkarni Mr. K. Reddy Mr. Harish Pandey Mr. Satish Kagliwal Head – R & D Head – Supply Chain Business Lead Managing Director Historical Income Statement Nath Bio-Genes’ P&L Statement Particulars (INR Mn) FY26 FY25 FY24 FY23 FY22 4,316 3,623 3,326 3,013 2,783 Total Revenue 2,403 2,289 1,991 1,667 1,544 Gross Profit 56% 63% 60% 55% 56% Gross Margin (%) 525 523 505 489 373 EBITDA 12% 14% 15% 16% 13% EBITDA Margin (%) 39 38 32 30 31 Depreciation 133 96 91 101 106 Finance Cost 431 436 388 363 254 PBT (before exceptional) 384 416 367 352 215 Adjusted PAT 9% 11% 12% 12% 9% PAT Margin (%) 23.42 22 21.6 18.5 11.3 Historical Balance Sheet Assets (INR Mn) FY26 FY25 FY24 FY23 FY22 Liabilities (INR Mn) FY26 FY25 FY24 FY23 FY22 Fixed Assets 2,437 2,430 2,406 2,340 2,329 Share Capital 190 190 190 190 190 Other Intangible 56 72 88 104 120 Assets Financial Assets 268 61 61 51 51 Reserves & Surplus 6,704 6,297 5,917 5,544 5,230 Loans 358 109 Other Non-current 426 442 421 225 218 Long-Term Borrowings 6 16 28 4 7 Assets Inventories 4,446 3,307 2,291 2,078 2,203 Long-term Provisions 49 35 30 28 26 Trade Receivables 838 888 943 973 879 Short Term Borrowings 1,212 1,095 1,055 1,048 923 Cash & Bank 707 876 755 380 42 Trade Payables 1,305 787 421 277 551 Balances Loans & Advances 1,620 1,665 1,629 1,711 1,502 Other Current Liabilities 1,340 1,735 1,112 830 482 Other Current Assets 32 69 67 68 76 Short Term Provisions 23 12 18 9 11 Total 10,829 10,168 8,771 7,930 7,419 Total 10,829 10,168 8,771 7,930 7,419